Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference
October 07 2021 - 7:00AM
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the
Company), a clinical-stage biopharmaceutical company, announced
that Seth Lederman, M.D., President and Chief Executive Officer of
Tonix, has been invited to participate in a panel discussion at the
A.G.P. Fall Virtual Biotech & Specialty Pharma Conference on
October 13, 2021.
Event Details
Event |
A.G.P. Fall Virtual Biotech & Specialty Pharma Conference |
Date & Time |
October 13, 2021 at 12:00 p.m.
ET |
Details |
Panel discussion moderated by
A.G.P. analyst, Jim Molloy |
Panel Title |
Long COVID & COVID
variants - How to tackle the still ongoing pandemic |
About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical
company focused on discovering, licensing, acquiring and developing
small molecules and biologics to treat and prevent human disease
and alleviate suffering. Tonix’s portfolio is primarily composed of
immunology and central nervous system (CNS) product candidates.
Tonix’s immunology portfolio includes a COVID-19 platform of
product candidates to prevent and treat COVID-19, to treat Long
COVID as well as to detect functional T cell immunity to COVID-19.
Tonix’s lead vaccine candidate for COVID-19, TNX-18001, is a live
replicating vaccine based on Tonix’s recombinant pox vaccine (RPV)
platform to protect against COVID-19, primarily by eliciting a T
cell response. Tonix reported positive efficacy data from animal
studies of TNX-1800 in the first quarter of 2021 and expects to
start a Phase 1 study in humans in the first half of 2022.
TNX-35002 (sangivamycin) is a small molecule antiviral drug to
treat acute COVID-19 and is in the pre-Investigational New Drug
(IND) stage of development. TNX-102 SL3 (cyclobenzaprine HCl
sublingual tablets) is a small molecule drug being developed to
treat Long COVID, a chronic condition, and is also in the pre-IND
stage. Finally, Tonix is developing TNX-21004, an in vivo
diagnostic to measure the presence of functional T cell immunity to
COVID-19. Tonix intends to initiate a first-in-human clinical study
of TNX-21004 in the fourth quarter of 2021, pending IND clearance.
Tonix’s immunology portfolio also includes biologics to address
immunosuppression, cancer, and autoimmune diseases. The Company’s
CNS portfolio includes both small molecules and biologics to treat
pain, neurologic, psychiatric and addiction conditions. Tonix’s
lead CNS candidate, TNX-102 SL3, is in mid-Phase 3 development for
the management of fibromyalgia.
1TNX-1800 is an investigational new biologic and
has not been approved for any indication. TNX-1800 is based on
TNX-801, live horsepox virus vaccine for percutaneous
administration, which is in development to protect against smallpox
and monkeypox. TNX-801 is an investigational new biologic and has
not been approved for any indication.
2TNX-3500 is an investigational new drug at the
pre-IND stage of development and has not been approved for any
indication.
3TNX-102 SL is an investigational new drug and
has not been approved for any indication.
4TNX-2100 is an investigational new biologic and
has not been approved for any indication.
This press release and further information about
Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on Tonix's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, the risks related to
to failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations; delays and uncertainties caused by the global
COVID-19 pandemic; risks related to the timing and progress of
clinical development of our product candidates; our need for
additional financing; uncertainties of patent protection and
litigation; uncertainties of government or third party payor
reimbursement; limited research and development efforts and
dependence upon third parties; and substantial competition. As with
any pharmaceutical under development, there are significant risks
in the development, regulatory approval, and commercialization of
new products. Tonix does not undertake an obligation to update or
revise any forward-looking statement. Investors should read the
risk factors set forth in the Annual Report on Form 10-K for the
year ended December 31, 2020, as filed with the Securities and
Exchange Commission (the “SEC”) on March 15, 2021, and periodic
reports filed with the SEC on or after the date thereof. All
Tonix's forward-looking statements are expressly qualified by all
such risk factors and other cautionary statements. The information
set forth herein speaks only as of the date thereof.
CONTACTS
Jessica Morris (corporate)Tonix
Pharmaceuticalsinvestor.relations@tonixpharma.com(862) 904-8182
Olipriya Das, Ph.D.
(media)Russo PartnersOlipriya.Das@russopartnersllc.com
(646) 942-5588
Peter Vozzo (investors)ICR
Westwickepeter.vozzo@westwicke.com (443) 213-0505
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2023 to Apr 2024